Clinical Trials

128 enrolled

Other solid neoplasm

Solid Tumor

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT02143219 2026-04-15

PAMELA70

72 enrolled 7 charts

Pancreatic Metastatic Cancer

NCT03161522 2026-04-15

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

100 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

105 enrolled

Borderline Resectable Pancreatic Adenocarcinoma

NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT03323463 2026-04-13

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

316 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

66 enrolled

Rectal Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

3 enrolled

Phase 2 Not yet recruiting

Stomach Neoplasms

NCT07419464 2026-04-09

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

46 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03764553 2026-04-07

LyRICX

320 enrolled

Esophageal Neoplasms

NCT05677490 2026-04-07

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

382 enrolled

Adenocarcinoma Of Esophagus

NCT07283939 2026-04-07

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Phase NA Recruiting

420 enrolled

Phase 2/3 Active not recruiting

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

DermatologicGastrointestinal

Colorectal Neoplasms

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT02366819 2026-03-30

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Phase 4 Suspended

36 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04703101 2026-03-30

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

25 enrolled

Rectal Neoplasms

NCT06538623 2026-03-24

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

40 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

14 enrolled

Head and Neck Neoplasms

NCT02359968 2026-03-18

PROTECT

106 enrolled

Esophageal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

60 enrolled

Phase 3 Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Active not recruiting

2 enrolled

Colonic Neoplasms

NCT06269978 2026-03-10

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

24 enrolled

Colorectal Neoplasms

NCT05491512 2026-03-09

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

121 enrolled

Phase 1/2 Not yet recruiting

Oropharyngeal Neoplasms

NCT07456852 2026-03-09

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

60 enrolled

Gastrointestinal Neoplasms

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

46 enrolled 15 charts

Pancreatic Neoplasms

NCT04380545 2026-03-06

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Phase 1/2 Recruiting

15 enrolled

Carcinoma, Hepatocellular

NCT07070466 2026-03-06

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

40 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT04230187 2026-03-05

TRIBE-C

528 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

30 enrolled

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Phase 4 Not yet recruiting

Rectal Neoplasms

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

42 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

214 enrolled

Phase 2 Enrolling by invitation

Squamous Cell Carcinoma of Head and Neck

NCT07441369 2026-03-02

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

16 enrolled

Phase 2 Not yet recruiting

Liver Metastases From Colorectal Cancer (mCRC)

NCT07176182 2026-02-27

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

236 enrolled

Phase 2/3 Not yet recruiting

Rectal Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Phase 1 Active not recruiting

Biliary Tract Neoplasms

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

38 enrolled

Tumor-Agnostic

Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Phase 2 Not yet recruiting

30 enrolled